ライフサイエンスコーパス: panel

1 s were imputed to the 1000 Genomes reference panel.

2 ith sensorial analysis obtained by a trained panel.

3 ay and imputed to the 1000 Genomes reference panel.

4 mmunophenotyping cytometry by time-of-flight panel.

5 on SNPs unique to the 1000 Genomes reference panel.

6 Consensus panel.

7 abidopsis (Arabidopsis thaliana) association panel.

8 using the 1000 Genomes multiethnic reference panel.

9 s among the related physicians and an expert panel.

10 ing datasets from a recombinant inbred mouse panel.

11 in the setting of comprehensive and targeted panels.

12 tic testing encompasses ever-increasing gene panels.

13 Panel 1 included pancytokeratin (AE1/AE3), PD-L1, CD4, C

14 Consensus statement from the panel: (1) Dedicated ophthalmic screening is recommended

15 ), PD-L1, CD4, CD8, CD3, CD68, and DAPI, and Panel 2 included pancytokeratin, PD-1, CD45RO, granzyme

16 Yields were greater for epilepsy panels (28 of 96 [29.2%]; P < .001) and whole exomes (5

17 In Panel 3-Arm 1 and Panel 3-Arm 2, 6/7 (86%) GT1a + ribavi

18 In Panel 3-Arm 1 and Panel 3-Arm 2, 6/7 (86%) GT1a + ribavirin and 4/8 (50%)

19 c nevi (n = 19), followed by a targeted gene panel (785 genes) characterization of melanocytic nevi (

20 A blinded independent expert panel adjudicated all events.

21 re we report the Anabaptist Genome Reference Panel (AGRP), the first whole-genome catalogue of varian

22 The panel also identified key areas for further investigatio

23 The guideline panel also made conditional recommendations for offering

24 assay Luminex xTAG Gastrointestinal Pathogen Panel, an in-house five-virus panel and bacterial cultur

25 the National Cancer Institute's 60-cell line panel and allowed us to obtain an X-ray co-crystal struc

26 tinal Pathogen Panel, an in-house five-virus panel and bacterial culture.

27 Methods ASCO convened an Expert Panel and conducted a systematic review of the medical l

28 of the TIP60 complex, both in the cell line panel and in a human tumor data set.

29 ne tongue, sensory perception with a trained panel and in vivo retention of sodium ions in human volu

30 periments involving a human cancer cell line panel and mouse xenografts revealed that 6OTD exhibits a

31 re, 95% CI 0.77-0.89; p<0.0001) to 0.91 (for panel and REVEAL 0.87-0.96; p<0.0001) and improving recl

32 The blood chemistry panel and the comprehensive blood analysis showed no inc

33 tforms were highly sensitive, both the Agena panel and Thermo Fisher NGS fusion panel reported minor

34 forms (Nanostring Elements, Agena LungFusion panel and ThermoFisher NGS fusion panel) to those obtain

35 ompliant neuromuscular blocking agent (NMBA) panels and 17/44 (39%) lacked a NAP6-defined extended pa

36 e identified; three are detected in multiple panels and are associated with starch-at-maturity, sucro

37 population-specific sequences in imputation panels and exemplify the power gains afforded by populat

38 he findings were reviewed by two independent panels and used to estimate diagnostic accuracy and conf

39 ory tests may not be present in current test panel arrangements.

40 se findings highlight the generated minigene panel as a flexible platform for the query of splicing-d

41 indication-specific single gene assays, gene panel assays that test for genes selected for their role

42 ve diagnosis was made by an expert consensus panel based on published criteria.

43 luated the Portrait Staph ID/R blood culture panel (BCP) multiplex PCR assay (Great Basin Scientific,

44 As flow panels become more complex, detection of minor immune ce

45 t a novel approach to enrich the target gene panel by microdroplet PCR.

46 We identified these panels by downselection after hierarchical clustering of

47 Use of standard virus panels can facilitate comparison of results across studi

48 C predominates, here we describe three virus panels, chosen from 200 well-characterized clade C envel

49 Methods An Update Panel conducted a targeted systematic literature review

50 Commercial test panel configurations are relatively constant over time,

51 For each intervention, the panel considered its confidence in the estimated effects

52 ert opinion of a multidisciplinary consensus panel consisting of neuroendocrine tumor experts, includ

53 A panel consisting of these three proteins had an area und

54 Each of those panels contains a series of X-Y plots depicting expressi

55 In the blind trial set, the panel correctly classified 93.33% AAAD+ patients and 86.

56 urrent Population Survey cross sections with panel data from de-identified tax records.

57 e principle accepts unique problems, such as panel decisions about scientific or artistic merit, and

58 An adjudication panel determined ILD hospitalization and death.

59 Results The ASCO Expert Panel determined that the ACS HNC Survivorship Care Guid

60 A trained sensory panel determined the bitterness character profile of eac

61 ew uses for the Drosophila Genetic Reference Panel (DGRP) in detection of background alleles that inf

62 ng data from large-scale European population panels (directly sequenced and imputation based).

63 ne and Nipavan Chiamvimonvat as speakers and panel discussants.

64 The workshop presentations and panel discussions focused on current understanding and k

65 y subcommittees and then modified after full-panel discussions.

66 ech industries including semiconductor, flat panel display, and solar photovoltaic industries.

67 Reports from 22 EQA panels distributed in 2005-2016 were analysed.

68 rimary care providers with their own patient panel doubled.

69 is applicable to clinical practice guideline panels drafting recommendations, physicians using clinic

70 ting expression levels of subsystems of that panel, e.g. subsystems within the central dogma panel in

71 Recommendations The ASCO Expert Panel emphasized that caring for HNC survivors requires

72 Use of standardized panels enables direct comparisons of data from different

73 fatty acids and texture profiles and sensory panel evaluations were considered.

74 evaluation of a WHO international reference panel for HEV genotypes (code 8578/13) showed viral load

75 dded to the US Recommended Uniform Screening Panel for newborns, but whether state implementation of

76 ingle nucleotide polymorphisms (SNPs) on the panel from previous studies, and genome-wide association

77 enable efficient selection of RNA biomarker panels from platelet RNA-sequencing libraries (n = 779).

78 The frequency of pathogenic variants in 21 panel genes identified in 41611 consecutively tested whi

79 Results from panel genetic testing and WGS were compared.

80 In 20 of 41 participants, panel genetic testing identified variants classified as

81 of genotype imputation to a dense reference panel given genotype likelihoods computed from ultralow

82 llection to discharge was 3.4 days in the GI panel group versus 3.9 days in the controls (P = 0.04).

83 Myeloid mutation panels have identified somatic variants in patients with

84 n Heart Association and 2004 Adult Treatment Panel III recommendations in HIV-infected adults and eva

85 ed heritability estimate for Adult Treatment Panel-III MetS of 0.24 (95% CI, 0.11-0.36) and for the M

86 The GI panel improved patient care by rapidly identifying a bro

87 An expert panel in psoriasis, pediatric dermatology, pediatric rhe

88 ation of targeted next-generation sequencing panels in countries with limited diagnostic resources.

89 el, e.g. subsystems within the central dogma panel include transcription, translation and protein mat

90 Our next generation sequencing panel incorporated 38 inherited arrhythmia syndrome cand

91 ted mass spectrometry of a surrogate peptide panel is a powerful method to study the dynamics of prot

92 Thus, the effective thickness of the panel is lengthened introducing its quarter wavelength r

93 Results The Panel is proposing 11 recommendations with strong agreem

94 different viruses from a standard influenza panel is reported.

95 The ePlex respiratory pathogen panel (RP panel) is a novel molecular biology-based assay, develop

96 al, radiologic, or serologic), the guideline panel made conditional recommendations against making a

97 d 17/44 (39%) lacked a NAP6-defined extended panel; many failed to screen all cases for chlorhexidine

98 ing older models such as the Mouse Diversity Panel (MDP), and newer models that include the Collabora

99 showed drug IC50 value greater than the cell panel median and lacked early S-phase arrest.

100 During an expert panel meeting that took place during the 9th C1 Inhibito

101 WHO collaborative study participants for all panel members (genotypes 1 to 4).

102 The panel methodologist assigned ratings to the selected stu

103 Of this miRNA panel, miR-26a was the most effective in reducing leukem

104 stomized targeted next-generation sequencing panel (Miseq).

105 Longitudinal panel modeling evaluated association between annual SMR

106 Cross-lagged panel models and linear mixed-effects models were used t

107 5 individuals had either cardiomyopathy gene panel (n=65) or known variant testing (n=10).

108 empirically, that the size of the reference panel needs to scale with the GWAS sample size; this has

109 We estimated panel-negative binomial models on a subset of beneficiar

110 on studies, imputed using a merged reference panel of 1,000 Genomes and UK10K data, totalling 6,200 c

111 ed next-generation sequencing using a custom panel of 101 CV-associated genes.

112 d on the relative abundance, we identified a panel of 11 proteins to distinguish CRC from AT.

113 lymphoblastoid cell lines, was applied to a panel of 12 patient-derived xenograft (PDX) models of gl

114 We have analyzed a panel of 17 KRAS mutant lung cancer cell lines classifie

115 CPROBE) cohort of 1235 adults, we selected a panel of 214 36 with stage 1 or 2 CKD, 99 with stage 3 C

116 used as features to predict sensitivity to a panel of 27 drugs.

117 study was conducted on a well-characterized panel of 279 human sera from the CDC, comparing ELISAs u

118 ted individuals using a large, multi-subtype panel of 30 tier 2-3 Env-pseudotyped viruses.

119 ng a 1-h EGF stimulation time course using a panel of 35 antibodies.

120 correlated to MYC/MYCN/MYCL1 expression in a panel of 35 cancer cell lines.

121 We sequenced whole genomes or a panel of 365 genes on 299 samples from 170 patients with

122 A panel of 57 organisms corresponding to 10 different spec

123 From this, we identified a panel of 6 genes, ALDH1A1, HSP90AB1, KIT, KRT16, SPRR3 a

124 nd is selective for the JAK family against a panel of 97 kinases.

125 Using a panel of AMD biomarkers and candidate drug screening, co

126 osphorylation, and induced cytotoxicity in a panel of AML cell lines.

127 dulate the TLR4 signaling, we present here a panel of amphiphilic guanidinocalixarenes whose structur

128 the pharmacokinetics and tumor delivery of a panel of anti-EphA2 monoclonal antibodies (mAbs) with an

129 b, the corresponding allergen Bet v 1, and a panel of antibodies specific for peptides spanning the C

130 ted its ability to isolate binders to a wide panel of antigens.

131 The algorithm outperformed the panel of ataxia experts (p = 0.001).

132 here that NOTCH3 signals constitutively in a panel of basal breast cancer cell lines and in more than

133 wk after each dosage, we studied a complete panel of biochemical blood variables to detect possible

134 eneous subgroups based on the endophenotype [panel of biomarkers]) with the aim to refine the managem

135 To characterize the temporal pattern of a panel of blood and urinary biomarkers in an animal model

136 er (T/F) clones for their sensitivities to a panel of bNAbs in cell-free and cell-to-cell infection a

137 ed reporter assay, we screened C4a against a panel of both known and orphan G protein-coupled recepto

138 The benefit of the commercially available panel of BV components is questionable, due to the insuf

139 ing-based screening of an shRNA library on a panel of cancer cells of different origins as well as no

140 proliferation, and were more sensitive to a panel of cancer drugs compared with GC of a more differe

141 ent target antigen-restricted apoptosis in a panel of cancer lines and in primary patient-derived can

142 measure differences in BER capacity across a panel of cell lines collected from healthy individuals,

143 Staphylococcus aureus expresses a panel of cell wall-anchored adhesins, including proteins

144 Here, using a panel of cell- and compartment-specific IFN-gamma recept

145 A large panel of common and isoform-specific peptides was monito

146 ycorrhizal inoculation was investigated in a panel of diverse maize lines.

147 A large panel of diverse tier-2 isolates from clades B and C was

148 tes virus replication, can be inhibited by a panel of drugs that are commercially available.

149 An external quality assessment panel of eight samples was also tested.

150 severe malaria on levels of IE adhesion to a panel of endothelial receptors.

151 out of 21 HIV-1 strains from a standardized panel of epidemiologically relevant HIV-1 subtypes.

152 ction of CD4(+) and CD8(+) T cells against a panel of established blood cancers and primary, patient-

153 An international panel of experts endorsed consensus diagnostic criteria

154 onal Academy of Sciences recently convened a panel of experts to undertake a comprehensive study of c

155 Third, WHO convened a multidisciplinary panel of experts who assessed the review findings and re

156 To develop the BEC, the AAP convened a panel of experts with knowledge of CBCT and substantial

157 viability of over 50% when tested against a panel of four pancreatic cancer cell lines in vitro.

158 We evaluated the impact of a panel of FoxP3 mutants on its transcriptional activity a

159 Here we describe a panel of genetic screens to identify genes required for

160 ere able to mediate the binding of a diverse panel of gp120 proteins to alpha4beta7 in an in vitro ce

161 aluation of antibacterial activity against a panel of Gram-positive and Gram-negative bacteria reveal

162 , and chloral hydrate), to ethanol, and to a panel of halogenated methanes and alcohols.

163 d allele-specific quantification assays to a panel of HD lymphoblastoid cell lines, each carrying the

164 of the enzyme inhibitory activity against a panel of HDAC isoforms revealed these compounds had stro

165 on can still be injected, thus extending the panel of host cells manipulated to the benefit of the pa

166 element signalling pathways and activated a panel of IFN-regulated genes, antiviral mediators and tr

167 splayed dominant ADCP activity compared to a panel of IgG1 MAbs.

168 omeostasis, with upregulated expression of a panel of immune-regulatory genes, which was distinctly d

169 r-targeting mAb, anti-CD20, with an extended panel of immunomodulatory mAbs.

170 vasion strategy in which Ct presents a large panel of irrelevant antigens to the immune system to blo

171 ng, we constructed and characterized a large panel of isogenic H. pylori strains that differ primaril

172 bolomics measurements across a comprehensive panel of kinases/phosphatases knockouts and time-resolve

173 p) retaining better efficacy against a broad panel of known INSTI resistant mutants than any analogue

174 In addition to an extended bacterial panel of laboratory strains, all 3 molecules rapidly acc

175 recognition of such a potential obstacle, a panel of leading experts in the field attempts here to d

176 s positively correlated with expression of a panel of lipid-associated genes, indicating a role of SL

177 2 in combination with Bcl-XL inhibition on a panel of liver cancer cells.

178 ited strong activity in vitro against a wide panel of M. abscessus isolates and in infected macrophag

179 Methods ASCO convened a multidisciplinary panel of medical oncology, psychiatry, nursing, hospice

180 sting activity profiles when co-treated in a panel of metal(II) cations in MIC assays.

181 A panel of minigenes of varying splicing potential were in

182 acted MM cell growth and survival in a large panel of MM cell lines and primary MM cells alone and in

183 ns of 4,6-tethered glucosazide donors with a panel of model acceptors revealed the effect of acceptor

184 Using a panel of monoclonal antibodies (MAbs) that recognize kno

185 Expression of DHRS9 within a panel of monocyte-derived macrophages was investigated b

186 (+)-1d, showed remarkable selectivity over a panel of more than 15 receptors as well as good chemical

187 on profiles of each of the Ras isoforms in a panel of mouse tissues derived from a full developmental

188 is of the Cdc42 interface on ACK, creating a panel of mutant proteins with which we can now describe

189 A cutoff-based score using the panel of nine proteins provided prognostic information i

190 We show that MICU1 is overexpressed in a panel of ovarian cancer cell lines and that MICU1 overex

191 e response kinetics to BRAF inhibition for a panel of patient-derived BRAF(V600) -mutant melanoma cel

192 through an analysis of TCR sequences using a panel of peptide and major histocompatibility complex (p

193 kers for detecting malignant potential was a panel of peptides from mucin-5AC and mucin-2, which coul

194 cyclopropenones were further treated with a panel of phosphine probes, and reaction rates were measu

195 allowed for a high-throughput screening of a panel of polymer carriers toward efficient cytosolic del

196 Using a panel of preterm transgenic mice, we show that epidermis

197 rious IEM based on reliable measurement of a panel of primary or secondary biomarkers above an upper

198 ties, we developed SNPDelScore, which uses a panel of proposed methods for quantifying deleterious ef

199 t interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand ass

200 In the present study, we develop a panel of rationally designed PPARdelta agonists.

201 dicates high affinity and selectivity over a panel of receptors including 5-HT2B subtype and hERG cha

202 y to sensitize TRAIL-mediated apoptosis in a panel of renal carcinoma cells.

203 Testing for a broad panel of respiratory viruses has been advocated as a use

204 tal cases and survivors, we identify a small panel of responding genes that act as strong predictors

205 Panel of retina specialists, image reading center expert

206 A panel of retina specialists.

207 A panel of retinal specialists determined the ground truth

208 ancestry of wild rice by analyzing a diverse panel of rice genomes consisting of 203 domesticated and

209 Here, we screened a panel of small molecules targeting epigenetic modulators

210 loss of macroH2A1 increased expression of a panel of stemness-associated genes and drove hyperactiva

211 chitinases and from this strain, generated a panel of strains where each expresses a single chitinase

212 A panel of systemic inflammatory markers and soluble vascu

213 rveyed trial units and members of the expert panel of the consensus meeting (N = 51), followed by pil

214 ophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and prote

215 We developed a panel of tunable expression platforms for the prominent

216 proneural glioma mouse model, we assessed a panel of tyrosine kinase inhibitors with different selec

217 Here, we isolated and characterized a panel of vaccine-elicited cross-reactive neutralizing MA

218 ies, using well-characterized controls and a panel of validation methods.

219 A diversity panel of wild species, landraces, and cultivars was sequ

220 as cardiovascular or noncardiovascular by a panel of WISE cardiologists masked to angiographic data.

221 laque reduction neutralization test) using a panel of WT JE strains at baseline, then after the boost

222 We selected large panels of 50 and 100 Envs either to characterize cross-r

223 further profiled this unique alkaloid across panels of discrete molecular targets.

224 Taken together our results provide panels of lipids that can differentiate between naive an

225 ed to analyze ligation products from complex panels of LISH probes ('LISH-seq'), which can be amplifi

226 scored the need for developing comprehensive panels of molecular markers for early disease detection

227 designed, synthesized, and evaluated against panels of tetracycline- and multidrug-resistant Gram-pos

228 n ice-free areas under two Intergovernmental Panel on Climate Change (IPCC) climate forcing scenarios

229 In this study, we use Intergovernmental Panel on Climate Change (IPCC) Tier II guidelines to qua

230 derestimated in the latest Intergovernmental Panel on Climate Change report.

231 rojections reported by the Intergovernmental Panel on Climate Change.

232 s as photon sources for next generation flat panel optical display devices, bio-medical applications,

233 iomyopathy genetic testing (either multigene panel or familial variant test) were recruited into the

234 an elevated (>80) donor-specific calculated panel reactive antibody level.

235 ffect modifiers, including public insurance, panel reactive antibody, delayed graft function, and ste

236 Having a calculated panel-reactive antibody (cPRA) of 80% or greater was ind

237 elopment of a numeric metric, the calculated panel-reactive antibody (CPRA) that predicts the likelih

238 tigens selected to give a virtual calculated panel-reactive antibody ranging 70% to 80% to improve HL

239 tus groups, with the exception of calculated panel-reactive antibody which was lowest in the D+/R- gr

240 The expert panel recognised that Zika virus alone may not be suffic

241 the Agena panel and Thermo Fisher NGS fusion panel reported minor fusions that were not detectable by

242 An expert panel reviewed current guidelines in the light of new da

243 Assessment Committee Oculoplastics and Orbit Panel reviewed for relevancy.

244 An Update Panel reviewed the identified abstracts.

245 An expert panel reviewed the results of the MINDACT study along wi

246 The ePlex respiratory pathogen panel (RP panel) is a novel molecular biology-based assa

247 blished on these topics, the strength of the panel's recommendations is classified as SORT level C ex

248 urvival was preceded by an adverse change in panel score in paired samples from 43 incident patients

249 Panel sequencing was successful for 97% (342/351) of tum

250 The validation panel, sequencing analytics, and raw sequences could fac

251 t in which we manipulated the temperature of panels set on the seafloor to provide a realistic and re

252 three HER2 overexpressing cell lines in this panel, SKBr3 and BT474 were highly sensitive to treatmen

253 emonstrates the versatility of a hiPSC-based panel spanning the mutational heterogeneity within a sin

254 We conducted a panel study in a representative sample of school-age chi

255 al cost figures from the Medical Expenditure Panel Survey (MEPS), provided by the Agency for Healthca

256 3 were obtained from the Medical Expenditure Panel Survey database.

257 0%, taking the official established method, "PANEL TEST", as reference.

258 The yield of cardiomyopathy gene panel testing was 9%.

259 o determine the yield of cardiomyopathy gene panel testing, distinguish the yield of testing for LVNC

260 ation carriers ascertained through multigene panel testing, evaluate their phenotype, and compare the

261 S detected nearly all variants identified on panel testing, provided 1 new diagnostic finding, and al

262 in cardiomyopathy but not included in prior panel testing: a pathogenic protein tyrosine phosphatase

263 in CHEK2), all identified through multigene panel tests.

264 ot masked to treatment, but the adjudication panel that reviewed radiology and endoscopy was masked t

265 g rapidly, with growing use of multiple-gene panels that can yield uncertain results.

266 In the external quality assessment panel, the Xpert HCV Viral Load assay results (quantifie

267 ty, or when using expanded carrier screening panels, they recommend to compute residual risk based on

268 biomarkers that can be used in a blood-based panel to allow earlier identification of individuals at

269 igh-depth next-generation sequencing using a panel to assay affected tissue from a diverse cohort of

270 Clinical Oncology (ASCO) convened an Expert Panel to conduct a systematic review of the literature t

271 psies with AMR and in an extended human cell panel to determine their selectivity.

272 Clinical Oncology (ASCO) convened an Expert Panel to develop an evidence-based guideline to help est

273 was applied to each question, requiring the panel to evaluate and weigh the importance of the proble

274 PSO enabled selection of gene panels to diagnose cancer from TEPs, suggesting that swa

275 emase detection, inclusion in susceptibility panels to eliminate delays and subjectivity in initiatin

276 We selected panels to represent the diversity of bnAb neutralization

277 ndard reference reagents, particularly virus panels to study neutralization by antibodies, are crucia

278 LungFusion panel and ThermoFisher NGS fusion panel) to those obtained from ALK, ROS1 and RET FISH on

279 Panel-track supplement approval.

280 observed the following general patterns: (a) Panel traps were superior to multiple-funnel traps, (b)

281 An ASCO Expert Panel updated the literature search and reviewed the gui

282 monized, with marked variability in the NMBA panels used to identify safe alternatives.

283 cal care guidelines were addressed by expert panels using a modified Delphi process, termed the Conve

284 A small 12-Env panel was chosen to screen sera from vaccine trials or n

285 round modified Delphi process with an expert panel was conducted from June 8, 2015, to January 25, 20

286 vascular inflammation and its mechanisms, a panel was recently convened of world experts in immunolo

287 A trained panel was used to evaluate leaves, and chemical data wer

288 The protein panel was validated in 93 patients with idiopathic or he

289 Using this panel, we have largely defined the carbohydrate specific

290 iew and the consensus of a multidisciplinary panel, we have provided summary information and guidelin

291 sensory references used to train the sensory panel were chemically analysed and employed to reduce th

292 The most common organisms detected by the GI panel were enteropathogenic Escherichia coli (EPEC, n =

293 m, and members of the adjudication pathology panel were masked to vaccination groups.

294 xygen levels, heart rate, CBC, and metabolic panel were obtained before and after MBKDR administratio

295 nvasive tests, questionnaires, and biomarker panels were obtained.

296 Two members of a 14-person reading panel, who had undertaken training and standardization i

297 t of HCV infection in a primary care patient panel with and without the implementation of Project ECH

298 e expression measurements from 45 expression panels with summary GWAS data to perform 30 multi-tissue

299 ics of the BD Max extended enteric bacterial panel (xEBP) assay directly from unpreserved or Cary-Bla

300 A targeted 8-gene panel yielded 125 (32%) LP/P variants, 52 (14%) variants